Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Rechallenge in Pharmacovigilance in 2026: Causality Assessment and Drug Safety

This article explains how positive and negative drug rechallenge findings strengthen causality assessment, improve Individual Case Safety Report documentation, and support regulatory decision-making under WHO-UMC, Naranjo, EMA GVP Module VI, and ICH E2D frameworks worldwide.
  • Blog, Quality Management System
Drug safety specialist reviewing positive and negative rechallenge outcomes, adverse drug reaction data, and Individual Case Safety Report documentation.

Dechallenge in Pharmacovigilance in 2026: Causality Assessment and Safety Signal Review

Explore how dechallenge in pharmacovigilance supports causality assessment, safety signal review, and regulatory reporting. Learn how positive dechallenge, negative dechallenge, and rechallenge findings help pharmaceutical teams evaluate adverse drug reactions and improve Individual Case Safety Reports.
  • Blog, Quality Management System
Pharmacovigilance causality assessment workflow showing adverse drug reaction evaluation, dechallenge outcomes, and Individual Case Safety Report review